Butyrylcholinesterase as a diagnostic and therapeutic target for alzheimer’s disease

Current Alzheimer Research

Volumn 13, Issue 10, 2016, Pages 1173-1177

  Darvesh, Sultan ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b MOUNT SAINT VINCENT UNIVERSITY   (Canada)

Author keywords

Acetylcholinesterase; Amyloid; Cholinergic; Dementia; Neuroimaging; Phenothiazines

Indexed keywords

AMYLOID BETA PROTEIN; CARBONYL DERIVATIVE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; NEUROTRANSMITTER RECEPTOR; PHENOTHIAZINE DERIVATIVE; SEX HORMONE; ACETYLCHOLINE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; AUTORADIOGRAPHY; BRAIN CORTEX; CHOLINERGIC SYSTEM; CHOLINESTERASE INHIBITION; COGNITION; DRUG TARGETING; ENZYME ACTIVE SITE; HUMAN; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; METABOLISM;

ACETYLCHOLINE; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BUTYRYLCHOLINESTERASE; CEREBRAL CORTEX; CHOLINESTERASE INHIBITORS; HUMANS;

EID: 84986888447     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205013666160404120542     Document Type: Review

References (51)

1. Silver, A. The Biology of Cholinesterases Elsevier, Amsterdam: 1974.
2. Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 4 (2): 131-138 (2003).
3. Nicolet Y, Lockridge O, Masson P, Fontecilla-Camps JC, Nachon F. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem 278(42): 41141-41147 (2003).
4. Saxena A, Redman AM, Jiang X, Lockridge O, Doctor BP. Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. Biochemistry 36 (48): 14642-14651 (1997).
5. Darvesh S, Darvesh KV, McDonald RS, Mataija D, Walsh R, Mothana S, et al. Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem 51(14): 4200-4212 (2008).
6. Darvesh S, Pottie IR, Darvesh KV, McDonald RS, Walsh R, Conrad S, et al. Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem 18(6): 2232-2244 (2010).
7. Mesulam M, Guillozet A, Shaw P, Quinn B. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 9(1): 88-93 (2002).
8. Layer PG. Cholinesterases during development of the avian nervous system. Cell Mol Neurobiol 11: 7-33 (1991).
9. Lockridge O. Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses. Pharmacol Ther 148: 34-46 (2015).
10. Darvesh S, Kumar R, Roberts S, Walsh R, Martin E. Butyrylcholinesterase-Mediated enhancement of the enzymatic activity of trypsin. Cell Mol Neurobiol 21(3): 285-296 (2001).
11. Darvesh S, Grantham DL, Hopkins DA. Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation. J Comp Neurol 393(3): 374-390 (1998).
12. Darvesh S, Hopkins DA. Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. J Comp Neurol 463(1): 25-43 (2003).
13. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex 1(1): 103-116 (1991).
14. World Health Organization and Alzheimer’s Disease International: Dementia: A Public Health Priority. Geneva: World Health Organization 2012: pp. 92-93.
15. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2 (8000): 1403 (1976).
16. Perry EK, Perry RH, Blessed G, Tomlinson BE. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1: 189 (1977).
17. Bartus RT, Dean RL, 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 217 (4558): 408-414 (1982).
18. Coyle JT, Price DL, DeLong MR. Alzheimer’s disease: A disorder of cortical cholinergic innervation. Science 219: 1184-1190 (1983).
19. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database of Systematic Reviews. Issue 1. Art. No.:CD005593. DOI: 10.1002/14651858.CD005593 (2006).
20. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 71(4): 266-273 (2012).
21. Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 56 (10): 1095-1097 (1997).
22. Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol 11(8): 669-678 (2012).
23. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313(19): 1924-1938 (2015).
24. Mortimer JA. The Nun Study: risk factors for pathology and clinical-pathologic correlations. Curr Alzheimer Res 9(6): 621-627 (2012).
25. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the society of nuclear medicine and molecular imaging, and the Alzheimer's association. J Nucl Med 54 (3): 476-490 (2013).
26. Darvesh S. Butyrylcholinesterase radioligands to image Alzheimer's disease brain. Chem Biol Interact 203 (1): 354-357 (2013).
27. Geula C, Mesulam MM. Cholinesterases and the pathology of Alzheimer disease. Alzheimer Dis Assoc Disord 9(2): 23-28 (1995).
28. Guillozet AL, Smiley JF, Mash DC, Mesulam MM. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 42 (6): 909-918 (1997).
29. Darvesh S, Reid AG, Martin E. Biochemical and histochemical comparison of cholinesterases in normal and Alzheimer brain tissues. Curr Alzheimer Res 7(5): 386-400 (2010).
30. Mesulam MM, Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 36 (5): 722-727 (1994).
31. Irie T, Fukushi K, Akimoto Y, Tamagami H, Nozaki T. Design and evaluation of radioactive acetylcholine analogs for mapping brain acetylcholinesterase in vivo. Nucl Med Biol 21 (6): 801-808 (1994).
32. Kilbourn MR, Snyder SE, Sherman PS, Kuhl DE. In vivo studies of acetylcholinesterase activity using a labeled substrate, N-[11C]methylpiperdin-4-yl propionate ([11C]PMP). Synapse 22(2): 123-131 (1996).
33. Kikuchi T, Fukushi, K, Ikota, N, Ueda T, Nagatsuka S. Arano Y, et al. Synthesis of piperidinyl and pyrrolidinyl butyrates for potential in vivo measurement of cerebral butyrylcholinesterase activity. J Labelled Comp Radiopharm 44: 31-41 (2001).
34. Kuhl DE, Koeppe RA, Snyder SE, Minoshima S, Frey KA, Kilbourn MR. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses. Ann Neurol 59 (1): 13-20 (2006).
35. Kikuchi T, Okamura T, Zhang MR, Irie T. PET probes for imaging brain acetylcholinesterase. J Label Comp Radiopharm 56 (3-4): 172-179 (2013).
36. Aldridge WN, Reiner E., Eds. In: Enzyme inhibitors as substrates: Interactions of esterases with esters of organophosphorus and carbamic acids. Amsterdam: North-Holland Pub. Co. (1972).
37. Macdonald IR, Reid GA, Pottie IR, Martin E, Darvesh S. Synthesis and Preliminary Evaluation of Phenyl 4-123I-iodophenylcarbamate for Visualization of Cholinesterases Associated with Alzheimer's Disease Pathology. J Nucl Med 57(2): 297-302 (2016).
38. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 26(40): 10129-10140 (2006).
39. Reid GA, Darvesh S. Butyrylcholinesterase-knockout reduces brain deposition of fibrillar beta-amyloid in an Alzheimer mouse model. Neuroscience 298: 424-435 (2015).
40. Perry EK, Perry RH, Blessed G, Tomlinson BE. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 4: 273-277 (1978).
41. Atack JR, Perry EK, Bonham JR, Candy JM, Perry RH. Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J Neurochem 47: 263-277 (1986).
42. Darvesh S, McDonald RS, Penwell A, Conrad S, Darvesh KV, Mataija D, et al. Structure-activity relationships for inhibition of human cholinesterases by alkyl amide phenothiazine derivatives. Bioorg Med Chem 13(1): 211-222 (2005).
43. Darvesh S, McDonald RS, Darvesh KV, Mataija D, Conrad S, Gomez G, et al. Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem 15(19): 6367-6378 (2007).
44. Swazey J. Chlorpromazine in Psychiatry: A Study of Therapeutic Innovation. Cambridge: MIT Press, (1974).
45. Darvesh S, Macdonald IR, Martin E. Selectivity of phenothiazine cholinesterase inhibitors for neurotransmitter systems. Bioorg Med Chem Lett 23(13): 3822-3825 (2013).
46. Darvesh S, Walsh R, Kumar R, Caines A, Roberts S, Magee D, et al. Inhibition of human cholinesterases by drugs used to treat Alzheimer disease. Alzheimer Dis Assoc Disord 17(2): 117-126 (2003)
47. Bailey JA, Lahiri DK. A novel effect of rivastigmine on presynaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease. J Neurochem 112(4): 843-853 (2010).
48. Bailey JA, Ray B, Greig NH, Lahiri DK. Rivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS One 6(7): e21954 (2011).
49. Greig NH, Utsuki T, Ingram DK, Wang Y, Pepeu G, Scali C, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci USA 102(47): 17213-17218 (2005).
50. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res 28(1): 235-242 (2000).
51. DeLano WL. The PyMOL Molecular Graphics System. DeLano Scientific, San Carlos, CA, USA. (http://www.pymol.org) (2002).